Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPTIVATE: Claseprubart (DNTH103) in Adults With CIDP
jRCT2031250771Phase 3Recruiting
- Sponsor
- Dianthus Therapeutics
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of claseprubart in chronic inflammatory demyelinating polyneuropathy (CIDP) (4 arms), sponsored by Dianthus Therapeutics. Primary endpoint: Time from first dose to relapse by adjusted INCAT (Part B). Started Apr 2026; status: recruiting.
02
Drugs
claseprubart
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on jRCT2031250771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250771.